ACCUNEB Drug Patent Profile
✉ Email this page to a colleague
When do Accuneb patents expire, and what generic alternatives are available?
Accuneb is a drug marketed by Pharmobedient and is included in one NDA.
The generic ingredient in ACCUNEB is albuterol sulfate. There are thirty-eight drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Accuneb
A generic version of ACCUNEB was approved as albuterol sulfate by SUN PHARM INDUSTRIES on December 5th, 1989.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ACCUNEB?
- What are the global sales for ACCUNEB?
- What is Average Wholesale Price for ACCUNEB?
Summary for ACCUNEB
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 65 |
| Clinical Trials: | 1 |
| Patent Applications: | 6,134 |
| Drug Prices: | Drug price information for ACCUNEB |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ACCUNEB |
| DailyMed Link: | ACCUNEB at DailyMed |
Recent Clinical Trials for ACCUNEB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Florida |
Paragraph IV (Patent) Challenges for ACCUNEB
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ACCUNEB | Inhalation Solution | albuterol sulfate | 0.021% | 020949 | 1 | 2005-10-19 |
| ACCUNEB | Inhalation Solution | albuterol sulfate | 0.042% | 020949 | 1 | 2004-04-06 |
US Patents and Regulatory Information for ACCUNEB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmobedient | ACCUNEB | albuterol sulfate | SOLUTION;INHALATION | 020949-002 | Apr 30, 2001 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmobedient | ACCUNEB | albuterol sulfate | SOLUTION;INHALATION | 020949-001 | Apr 30, 2001 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ACCUNEB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pharmobedient | ACCUNEB | albuterol sulfate | SOLUTION;INHALATION | 020949-002 | Apr 30, 2001 | 6,702,997 | ⤷ Start Trial |
| Pharmobedient | ACCUNEB | albuterol sulfate | SOLUTION;INHALATION | 020949-001 | Apr 30, 2001 | 6,702,997 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ACCUNEB
See the table below for patents covering ACCUNEB around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2002347948 | ⤷ Start Trial | |
| Australia | 2006202584 | ⤷ Start Trial | |
| Australia | 3297502 | ⤷ Start Trial | |
| Canada | 2464660 | SOLUTION D'INHALATION A BASE D'ALBUTEROL, ET SYSTEME, KIT ET METHODE PERMETTANT DE SOULAGER LES SYMPTOMES DE L'ASTHME PEDIATRIQUE (ALBUTEROL INHALATION SOLUTION, SYSTEM, KIT AND METHOD FOR RELIEVING SYMPTOMS OF PEDIATRIC ASTHMA) | ⤷ Start Trial |
| China | 100413494 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch